Molecular Cardiovascular Biology

Division Details

Division Data Summary

Research and Training Details

Number of Faculty12
Number of Research Fellows30
Number of Research Students19
Number of Support Personnel23
Direct Annual Grant Support$6,919,459
Peer Reviewed Publications54

Division Photo

No Photo information has been entered yet.

Significant Accomplishments

To begin editing, switch to edit mode, then click arrow on left and select "Edit".

Significant Publications

Sengupta A, Kalinichenko VV, Yutzey KE. FoxO1 and FoxM1 transcription factors have antagonistic functions in neonatal cardiomyocyte cell-cycle withdrawal andIGF1 gene regulation. Circulation research. 2013 Jan 18;112(2):267-77. PubMed PMID: 23152492. 

After birth, cardiac muscle cells stop proliferating and the heart grows primarily by increasing the size of cells.  In this publication, Sengupta et al report a novel genetic regulatory mechanism whereby FoxO and FoxM1 transcription factors regulate the withdrawal of cardiac muscle cells from cell cycle.  An additional novel finding is that these transcription factors are sensitive to the metabolic state of heart muscle that undergoes a switch from using primarily glucose to using fatty acids for energy during the neonatal period.  

Together these studies define a completely new regulatory mechanism for control of neonatal cardiomyocyte cell withdrawal.  Since these same regulatory mechanisms are associated with adult cardiac disease, these studies also have potential implications for cardiac repair and regeneration as well as development of new therapeutic approaches.

van Berlo JH, Maillet M, Molkentin JD. Signaling effectors underlying pathologic growth and remodeling of the heart.The Journal of clinical investigation. 2013 Jan 2;123(1):37-45. 

Cardiovascular diseases ultimately result in the failure of the heart to achieve its pumping function. This review discusses the development of new drugs that aim at maintaining the heart’s function with cardiovascular disease. This can primarily be achieved through the modulation of the neuro-hormonal cardiac response. Neuro-hormonal signals activate G protein coupled receptors which initiate cardio-protective and deleterious intracellular signals. 

While the currently available G protein coupled receptors drugs (i.e. beta-blockers or Angiotensin Receptors Blockers) indistinctly target all the G protein coupled receptors intracellular pathways, the development of biased G protein coupled receptor ligands constitutes a ground-breaking approach for the treatment of cardiovascular diseases because they specifically activate cardio-protective signaling pathways. Additionally, drugs that would acutely restore contractility (i.e. PKCa or Calcium Calmodulin Kinase II inhibitors) could constitute a significant adjunct to the currently available treatment options. 

Furthermore, a potential interesting therapeutic approach would be to reduce the levels of a non-contractile intracellular calcium pool known to contribute to the development of cardiac hypertrophy (i.e. non-selective cationic TRPC channels inhibitors). As the heart failure epidemic continues to rise despite the available treatments, the development of new drugs targeting all stages of heart disease is vital. 

Division Publications

Molecular Cardiovascular Biology Publications

  1. Antoniak S, Owens AP, 3rd, Baunacke M, Williams JC, Lee RD, Weithäuser A, Sheridan PA, Malz R, Luyendyk JP, Esserman DA, Trejo J, Kirchhofer D, Blaxall BC, Pawlinski R, Beck MA, Rauch U, Mackman N. PAR-1 contributes to the innate immune response during viral infection. J Clin Invest. 2013; 123:1310-22.
  2. Aprikyan AA, Khuchua Z. Advances in the understanding of Barth syndrome. Br J Haematol. 2013; 161:330-8.
  3. Auger-Messier M, Accornero F, Goonasekera SA, Bueno OF, Lorenz JN, van Berlo JH, Willette RN, Molkentin JD. Unrestrained p38 MAPK activation in Dusp1/4 double-null mice induces cardiomyopathy. Circ Res. 2013; 112:48-56.
  4. Bal NC, Maurya SK, Sopariwala DH, Sahoo SK, Gupta SC, Shaikh SA, Pant M, Rowland LA, Goonasekera SA, Molkentin JD, Periasamy M. Sarcolipin is a newly identified regulator of muscle-based thermogenesis in mammals. Nat Med. 2012; 18:1575-9.
  5. Belmonte SL, Blaxall BC. Conducting the G-protein Coupled Receptor (GPCR) Signaling Symphony in Cardiovascular Diseases: New Therapeutic Approaches. Drug Discov Today Dis Models. 2012; 9:e85-e90.
  6. Belmonte SL, Blaxall BC. G protein-coupled receptor kinase 5: exploring its hype in cardiac hypertrophy. Circ Res. 2012; 111:957-8.
  7. Bhuiyan MS, Gulick J, Osinska H, Gupta M, Robbins J. Determination of the critical residues responsible for cardiac myosin binding protein C's interactions. J Mol Cell Cardiol. 2012; 53:838-47.
  8. Blaxall BC, Baudino TA, Kirshenbaum LA. Cardiac fibroblasts and cellular cross talk in heart failure. J Cardiovasc Transl Res. 2012; 5:737-8.
  9. Bolte C, Zhang Y, York A, Kalin TV, Schultz Jel J, Molkentin JD, Kalinichenko VV. Postnatal ablation of Foxm1 from cardiomyocytes causes late onset cardiac hypertrophy and fibrosis without exacerbating pressure overload-induced cardiac remodeling. PLoS One. 2012; 7:e48713.
  10. Braitsch CM, Combs MD, Quaggin SE, Yutzey KE. Pod1/Tcf21 is regulated by retinoic acid signaling and inhibits differentiation of epicardium-derived cells into smooth muscle in the developing heart. Dev Biol. 2012; 368:345-57.
  11. Buchaklian AH, Helbling D, Ware SM, Dimmock DP. Recessive deoxyguanosine kinase deficiency causes juvenile onset mitochondrial myopathy. Mol Genet Metab. 2012; 107:92-4.
  12. Carruthers CA, Alfieri CM, Joyce EM, Watkins SC, Yutzey KE, Sacks MS. Gene Expression and Collagen Fiber Micromechanical Interactions of the Semilunar Heart Valve Interstitial Cell. Cell Mol Bioeng. 2012; 5:254-265.
  13. Correll RN, Molkentin JD. CaMKII does it again: even the mitochondria cannot escape its influence. Circ Res. 2013; 112:1208-11.
  14. Davis J, Burr AR, Davis GF, Birnbaumer L, Molkentin JD. A TRPC6-dependent pathway for myofibroblast transdifferentiation and wound healing in vivo. Dev Cell. 2012; 23:705-15.
  15. Davis J, Maillet M, Miano JM, Molkentin JD. Lost in Transgenesis: A User's Guide for Genetically Manipulating the Mouse in Cardiac Research. Circ Res. 2012; 111:761-77.
  16. Dhawan L, Liu B, Pytlak A, Kulshrestha S, Blaxall BC, Taubman MB. Y-Box Binding Protein 1 and RNase UK114 Mediate Monocyte Chemoattractant Protein 1 mRNA Stability in Vascular Smooth Muscle Cells. Mol Cell Biol. 2012; 32:3768-75.
  17. Drawnel FM, Wachten D, Molkentin JD, Maillet M, Aronsen JM, Swift F, Sjaastad I, Liu N, Catalucci D, Mikoshiba K, Hisatsune C, Okkenhaug H, Andrews SR, Bootman MD, Roderick HL. Mutual antagonism between IP(3)RII and miRNA-133a regulates calcium signals and cardiac hypertrophy. J Cell Biol. 2012; 199:783-98.
  18. Elrod JW, Molkentin JD. Physiologic functions of cyclophilin D and the mitochondrial permeability transition pore. Circ J. 2013; 77:1111-22.
  19. Fujimoto KL, Tobita K, Guan J, Hashizume R, Takanari K, Alfieri CM, Yutzey KE, Wagner WR. Placement of an elastic biodegradable cardiac patch on a subacute infarcted heart leads to cellularization with early developmental cardiomyocyte characteristics. J Card Fail. 2012; 18:585-95.
  20. Gao H, Wang F, Wang W, Makarewich CA, Zhang H, Kubo H, Berretta RM, Barr LA, Molkentin JD, Houser SR. Ca(2+) influx through L-type Ca(2+) channels and transient receptor potential channels activates pathological hypertrophy signaling. J Mol Cell Cardiol. 2012; 53:657-67.
  21. James J, Robbins J. Ablating a cardiac protein: causality at last. Circ Res. 2013; 112:1415-9.
  22. Kamal FA, Travers JG, Blaxall BC. G protein-coupled receptor kinases in cardiovascular disease: why "where" matters. Trends Cardiovasc Med. 2012; 22:213-9.
  23. Karch J, Molkentin JD. Is p53 the long-sought molecular trigger for cyclophilin D-regulated mitochondrial permeability transition pore formation and necrosis?. Circ Res. 2012; 111:1258-60.
  24. Lalani SR, Shaw C, Wang X, Patel A, Patterson LW, Kolodziejska K, Szafranski P, Ou Z, Tian Q, Kang SH, Jinnah A, Ali S, Malik A, Hixson P, Potocki L, Lupski JR, Stankiewicz P, Bacino CA, Dawson B, Beaudet AL, Boricha FM, Whittaker R, Li C, Ware SM, Cheung SW, Penny DJ, Jefferies JL, Belmont JW. Rare DNA copy number variants in cardiovascular malformations with extracardiac abnormalities. Eur J Hum Genet. 2013; 21:173-81.
  25. Le Grand F, Grifone R, Mourikis P, Houbron C, Gigaud C, Pujol J, Maillet M, Pagès G, Rudnicki M, Tajbakhsh S, Maire P. Six1 regulates stem cell repair potential and self-renewal during skeletal muscle regeneration. J Cell Biol. 2012; 198:815-32.
  26. Lorts A, Schwanekamp JA, Baudino TA, McNally EM, Molkentin JD. Deletion of periostin reduces muscular dystrophy and fibrosis in mice by modulating the transforming growth factor-β pathway. Proc Natl Acad Sci U S A. 2012; 109:10978-83.
  27. Lowey S, Bretton V, Gulick J, Robbins J, Trybus KM. Transgenic Mouse α- and β-Cardiac Myosins Containing the R403Q Mutation Show Isoform-dependent Transient Kinetic Differences. J Biol Chem. 2013; 288:14780-7.
  28. Maejima Y, Galeotti J, Molkentin JD, Sadoshima J, Zhai P. Constitutively active MEK1 rescues cardiac dysfunction caused by overexpressed GSK-3alpha during aging and hemodynamic pressure overload. Am J Physiol Heart Circ Physiol. 2012; 303:H979-88.
  29. Maillet M, van Berlo JH, Molkentin JD. Molecular basis of physiological heart growth: fundamental concepts and new players. Nat Rev Mol Cell Biol. 2013; 14:38-48.
  30. Martin ML, Belmonte SL, Ram R, Kamal FA, Blaxall BC. G-Protein-Coupled Receptors in the Heart. In: JA Hill, EN Olson, eds. Muscle: Fundamental Biology and Mechanisms of Disease. Waltham, MA: Academic Press; 2012:87-112.
  31. Martin ML, Blaxall BC. Cardiac intercellular communication: are myocytes and fibroblasts fair-weather friends?. J Cardiovasc Transl Res. 2012; 5:768-82.
  32. Michalek AJ, Howarth JW, Gulick J, Previs MJ, Robbins J, Rosevear PR, Warshaw DM. Phosphorylation modulates the mechanical stability of the cardiac myosin-binding protein C motif. Biophys J. 2013; 104:442-52.
  33. Miller EM, Wang Y, Ware SM. Uptake of cardiac screening and genetic testing among hypertrophic and dilated cardiomyopathy families. J Genet Couns. 2013; 22:258-67.
  34. Molkentin JD. Parsing good versus bad signaling pathways in the heart: role of calcineurin-nuclear factor of activated T-cells. Circ Res. 2013; 113:16-9.
  35. Muili KA, Wang D, Orabi AI, Sarwar S, Luo Y, Javed TA, Eisses JF, Mahmood SM, Jin S, Singh VP, Ananthanaravanan M, Perides G, Williams JA, Molkentin JD, Husain SZ. Bile acids induce pancreatic acinar cell injury and pancreatitis by activating calcineurin. J Biol Chem. 2013; 288:570-80.
  36. Nicholson CK, Lambert JP, Molkentin JD, Sadoshima J, Calvert JW. Thioredoxin 1 is essential for sodium sulfide-mediated cardioprotection in the setting of heart failure. Arterioscler Thromb Vasc Biol. 2013; 33:744-51.
  37. Parrott A, Ware SM. The Role of the Geneticist and Genetic Counselor in an ACHD Clinic. Prog Pediatr Cardiol. 2012; 34:15-20.
  38. Piao L, Fang YH, Parikh KS, Ryan JJ, D'Souza KM, Theccanat T, Toth PT, Pogoriler J, Paul J, Blaxall BC, Akhter SA, Archer SL. GRK2-Mediated Inhibition of Adrenergic and Dopaminergic Signaling in Right Ventricular Hypertrophy: Therapeutic Implications in Pulmonary Hypertension. Circulation. 2012; 126:2859-69.
  39. Powers C, Huang Y, Strauss A, Khuchua Z. Diminished Exercise Capacity and Mitochondrial bc1 Complex Deficiency in Tafazzin-Knockdown Mice. Front Physiol. 2013; 4:74.
  40. Previs MJ, Beck Previs S, Gulick J, Robbins J, Warshaw DM. Molecular mechanics of cardiac myosin-binding protein C in native thick filaments. Science. 2012; 337:1215-8.
  41. Ryan TD, Ware SM, Lucky AW, Towbin JA, Jefferies JL, Hinton RB. Left ventricular noncompaction cardiomyopathy and aortopathy in a patient with recessive dystrophic epidermolysis bullosa. Circ Heart Fail. 2012; 5:e81-2.
  42. Schulz EM, Correll RN, Sheikh HN, Lofrano-Alves MS, Engel PL, Newman G, Schultz Jel J, Molkentin JD, Wolska BM, Solaro RJ, Wieczorek DF. Tropomyosin dephosphorylation results in compensated cardiac hypertrophy. J Biol Chem. 2012; 287:44478-89.
  43. Sengupta A, Kalinichenko VV, Yutzey KE. FoxO1 and FoxM1 transcription factors have antagonistic functions in neonatal cardiomyocyte cell-cycle withdrawal and IGF1 gene regulation. Circ Res. 2013; 112:267-77.
  44. Suk HY, Zhou C, Yang TT, Zhu H, Yu RY, Olabisi O, Yang X, Brancho D, Kim JY, Scherer PE, Frank PG, Lisanti MP, Calvert JW, Lefer DJ, Molkentin JD, Ghigo A, Hirsch E, Jin J, Chow CW. Ablation of calcineurin Aβ reveals hyperlipidemia and signaling cross-talks with phosphodiesterases. J Biol Chem. 2013; 288:3477-88.
  45. Sutherland MJ, Wang S, Quinn ME, Haaning A, Ware SM. Zic3 is required in the migrating primitive streak for node morphogenesis and left-right patterning. Hum Mol Genet. 2013; 22:1913-23.
  46. Towbin JA, Ware SM, Jefferies JL. Congenital Cardiomyopathies. In: JA Hill, EN Olson, eds. Muscle: Fundamental Biology and Mechanisms of Disease. Waltham, MA: Academic Press; 2012:459-472.
  47. van Berlo JH, Maillet M, Molkentin JD. Signaling effectors underlying pathologic growth and remodeling of the heart. J Clin Invest. 2013; 123:37-45.
  48. Wang Y, Tanner BC, Lombardo AT, Tremble SM, Maughan DW, Vanburen P, Lewinter MM, Robbins J, Palmer BM. Cardiac myosin isoforms exhibit differential rates of MgADP release and MgATP binding detected by myocardial viscoelasticity. J Mol Cell Cardiol. 2013; 54:1-8.
  49. Weith AE, Previs MJ, Hoeprich GJ, Previs SB, Gulick J, Robbins J, Warshaw DM. The extent of cardiac myosin binding protein-C phosphorylation modulates actomyosin function in a graded manner. J Muscle Res Cell Motil. 2012; 33:449-59.
  50. Wirrig EE, Yutzey KE. Developmental Pathways in CAVD. In: E Aikawa, ed. Calcific Aortic Valve Disease. Rijeka, Croatia: InTech; 2013:59-104.
  51. Xu X, Kobayashi S, Chen K, Timm D, Volden P, Huang Y, Gulick J, Yue Z, Robbins J, Epstein PN, Liang Q. Diminished autophagy limits cardiac injury in mouse models of type 1 diabetes. J Biol Chem. 2013; 288:18077-92.
  52. Yar S, Chowdhury SA, Davis RT, 3rd, Kobayashi M, Monasky MM, Rajan S, Wolska BM, Gaponenko V, Kobayashi T, Wieczorek DF, Solaro RJ. Conserved Asp-137 Is Important for both Structure and Regulatory Functions of Cardiac α-Tropomyosin (α-TM) in a Novel Transgenic Mouse Model Expressing α-TM-D137L. J Biol Chem. 2013; 288:16235-46.
  53. Yutzey KE. Transcriptional Control of Cardiogenesis. In: JA Hill, EN Olson, eds. Muscle: Fundamental Biology and Mechanisms of Disease. Waltham, MA: Academic Press; 2012:35-46.
  54. Zhang L, Malik S, Pang J, Wang H, Park KM, Yule DI, Blaxall BC, Smrcka AV. Phospholipase Cε hydrolyzes perinuclear phosphatidylinositol 4-phosphate to regulate cardiac hypertrophy. Cell. 2013; 153:216-27.

Faculty, Staff, and Trainees

Faculty Members

Jeffrey Robbins, PhD, FAHA, FISHR, Professor
Leadership Executive Co-Director, Heart Institute; Associate Chair for Core Research; Endowed Chair for Molecular Cardiovascular Biology
Research Interests Mechanisms of Normal and Abnormal Cardiovascular function
Burns C. Blaxall, PhD, FAHA, Professor
Leadership Director, Translational Science
Research Interests Molecular and signaling mechanisms of heart failure; cardiac fibrosis; drug and therapeutic discovery
James Gulick, MS, Instructor
Research Interests Molecular interactions between certain cardiac contractile proteins and how such interactions can be altered by mutations that are associated with cardiomyopathies
Jeanne James, MD, Associate Professor
Leadership Director, Pediatric Cardiology Fellowship Program; Director, Mouse Echocardiography Core
Research Interests Echocardiography, Translational Research, Cardiovascular Genetics
Zaza Khuchua, PhD, Associate Professor
Research Interests Congenital cardiac disorders caused by inborn errors in mitochondrial energy-producing enzymes, and model systems to study molecular mechanisms of these diseases
Marjorie Maillet, PhD, Instructor
Research Interests Understanding signaling pathways that lead to heart disease
Jeffery Molkentin, PhD, Professor
Leadership Howard Hughes Medical Institute Investigator
Research Interests Molecular pathways that underlie heart disease and muscular dystrophy
Sudarsan Rajan, PhD, Assistant Professor
Research Interests Understanding contractile and regulatory proteins' gene expression and their role in maintaining normal cardiovascular function
Johannes van Berlo, MD, PhD, Instructor
Stephanie Ware, MD, PhD, Associate Professor
Leadership Director of Research and Development, Associate Medical Director, The Heart Institute Diagnostic Laboratory
Research Interests Genetics of pediatric heart disease
Joshua Waxman, PhD, Assistant Professor
Research Interests Molecular genetics of cardiovascular development
Katherine Yutzey, PhD, Professor
Research Interests Heart development and disease mechanisms


  • Federica Accornero, PhD, University of Turin, Italy
  • Sarah Beckman, PhD, University of Pittsburgh
  • Md. Shenuarin Bhuiyan, PhD, Tohoku University, Japan
  • Caitlin Braitsch, PhD, University of Cincinnati
  • Adam Burr, BS, University of Minnesota, Twin Cities
  • Santanu Chakraborty, PhD, Miami University
  • Rajshekhar Chatterjee, PhD, Washington University
  • Robert Nathan Correll, PhD, University of Kentucky
  • Jason Cowan, MS, University of Miami
  • Angela Damen, MAT, Miami University
  • Enrico D'Aniello, PhD, Marine Zoological Station Anton Dohrn, Italy
  • Jennifer Davis, PhD, Univeristy of Michigan, Ann Arbor
  • Allison Dixon, BS, Bellarmine University
  • Tracy Dohn, BS, Wittenberg University
  • John Elrod, PhD, Albert Einstein College of Medicine
  • Ming Fang, MS, Boise State University
  • Maria Gomez, BS, Xavier University
  • Ambrose Goonasekera, PhD, University of Rochester
  • Manish Gupta, PhD, University of Cincinnati
  • Yan Huang, PhD, University of Wyoming
  • Alexia Hulin, PhD, Cleveland Clinic
  • Cameron Ingram, , University of Cincinnati
  • Fadia Kamal, PhD, University of Rochester
  • Onur Kanisicak, PhD, University of Connecticut
  • Jason Karch, PhD, University of Cincinnati
  • Jennifer Kwong, PhD, Weill Medical College of Cornell University
  • Julie Lander, BS, Brigham Young University
  • Mary Lee, MS, Ball State University
  • Ruijie Liu, PhD, University of Illinois at Urbana Champaign
  • Jeffrey Lynch, PhD, University of Alberta, Canada
  • Amrita Mandal, MSc, University of Calcutta, India
  • Patrick McLendon, PhD, Virginia Polytechnical Institute and State University
  • Rashmi Ram, PhD, University of Rochester
  • Md. Abdur Razzaque, PhD, Tokyo Women's Medical University, Japan
  • Tara Rindler, PhD, University of Cincinnati
  • Ariel Rydeen, BS, University of Minnesota
  • Tobias Schips, PhD, Ulm University, Germany
  • Jeffrey Schubert, BS, College of Mount St. Joseph
  • Emily Schulz, PhD, University of Cincinnati
  • Jennifer Schwanekamp, MS, University of Cincinnati
  • Arunima Sengupta, PhD, Miami University
  • Mardi Sutherland, BS, University of Massachusetts, Boston
  • Muhammad Tariq, PhD, Quaid-I-Azam University, Pakistan
  • Andoria Tjondrokoesoemo, PhD, University of Medicine & Dentistry of New Jersey
  • Joshua Travers, BS, Rochester Institute of Technology
  • Davy Vanhoutte, PhD, University of Leuven, Belgium
  • Elaine Wirrig, PhD, Medical University of South Carolina
  • Erin Wissing, BA, DePauw University
  • Fuli Xiang, MD, PhD, University of Western Ontario, Canada

Division Collaboration

Allergy and Immunology; Human Genetics » Marc E. Rothenberg, MD, PhD, J. Pablo Abonia, MD, and Derek E. Neilson, MD
An open trial label of losartan in patients with eosinophilic esophagitis and connective tissue disorders.
Biomedical Informatics; Human Genetics » Bruce J. Aronow, PhD and Lisa J. Martin, PhD
Studying the genotype/phenotype correlations in pediatric cardiomyopathy.
Critical Care Medicine » Basilia Zingarelli, MD, PhD
Echocardiographic characterization of PPAR-gamma deficient mice in the setting of ischemia-reperfusion injury.
Experimental Hematology & Cancer Biology – Translational Labs » Carolyn M. Lutzko, PhD
The use of IPS cells to investigate genetic and epigenetic mechanisms of cardiomyopathy.
Experimental Hematology and Cancer Biology » Nicolas Nassar, PhD
Studying vascular requirements of Angiomotin.
Hematology; Experimental Hematology » Joseph S. Palumbo, MD and Jay L. Degen, PhD
Exploring the role of PAR-1 in cardiac disease.
Human Genetics » Daniel R. Prows, PhD
Echocardiographic characterization of right ventricular dysplasia in mice.
Human Genetics » Teresa Smolarek, PhD and Sarah L. Zimmerman, PhD
A database registry of patients with cardiovascular malformations and chromosome microarray abnormalities.

Grants, Contracts, and Industry Agreements

Molecular Cardiovascular Biology Grants

Grant and Contract AwardsAnnual Direct

Accornero, F

PGF Role in Regulating Cardiac Remodeling

Bhuiyan, S

Functional Significance and Regulation of cMyBP-C Binding to Actin

Blaxall B

A Role for Mena in the Heart
R01 HL 0898802/22/13-01/31/14$87,612
Extracellular Matrix Remodeling and Fibrosis
R01 GM 09734708/15/12-11/30/15$45,991
Small Molecule Targeting of MLK3 for Heart Failure
Targeting of B-AR/GBy Signaling in the Heart with Small Molecules
R01 HL 09147505/31/13-05/30/14$235,620

Dohn, T

Training in Cardiovascular Biology
T32 HL 00738201/01/13-12/31/13$14,688

Gupta, M

Role of Myosin Binding Protein-C Phosphorylation in Cardiac Function

Khuchua, Z

A Mouse Model of Barth Syndrome, a Mitochondrial Cardiolipin Disorder
R01 HL 10886707/07/11-03/31/15$238,000

Kwong, J

Defining the Role of SLC25a35 as a Regulator of the Mitochondrial Permeability Transition Pore and Cardiomyocyte Death

Lee, M

Differential Twist1 Dimer Function and Gene Regulation in Valve Progenitor Cells

McLendon, P

The Role of Impaired Protein Degradation Pathways in CryABR120G-Mediated Desmin-R
F32 HL 11255801/11/12-03/11/13$8,990

Molkentin, J

Ca Signaling Domains Programming Cardiac Hypertrophy
P01 HL 08010108/01/11-05/31/16$271,987
Cardiac Hypertrophic Intracellular Signaling Pathways
R01 HL 06292702/01/09-12/31/13$222,750
Improving Cardiac Function after Myocardial Infarction
P01 HL 10880605/07/12-03/31/17$255,000
Molecular Pathways Controlling Cardiac Gene Expression
R37 HL 06056207/01/08-06/30/13$247,500
Mechanisms of TGF Regulated Fibrosis in Muscular Dystrophy
P01 NS 07202707/01/11-06/30/16$250,000
Thrombospondin 4 Regulates Adaptive ER Stress Response
R01 HL 10592401/01/11-12/31/14$312,920

Rajan, S

Translational and Post-translational Regulation of Tropomyosin in Normal and Cardiomyopathic Hearts

Robbins , J

A TG Rabbit Model for the Functional Effects of FHC Mutations in B-Cardiac Myosin
R21 HL 11184707/15/12-06/30/14$9,600
Cardiac Myosin Binding Protein-C: Structure, Function and Regulation
P01 HL 05940802/01/10-01/31/15$307,959
Proteotoxicity: An Unappreciated Mechanism of Heart Disease
Signaling Processes Underlying Cardiovascular Function
P01 HL 06977901/11/08-12/31/12$1,219,260

Schulz, E

Training in Cardiovascular Biology
T32 HL 00738202/01/13-01/31/14$22,904

Sengupta, A

FOXO Function in Cardiomyocytes During Development and Disease

Tariq, M

Identification of Novel Human X-Linked Heterotaxy Genes

van Berlo, J

Functional Relevance and Extent of Endogenous Cardiac Regeneration by C-Kit Positive Stem Cells
K99 HL 11285206/04/12-03/31/17$121,660

Ware, S

Genetic and Epigenetic Mechanisms in Cardiomyopathy
Genetic Registry for Pediatric Heart Disease: The CCVM Consortium
Genotype-Phenotype Association in Pediatric Cardiomyopathy
R01 HL 11145904/01/12-03/31/16$987,826
Uncovering Novel Genetic Causes and Risk in Congenital Heart Disease Patients
BWF #100849607/01/09-06/30/15$150,000

Waxman, J

Coup-tf Dependent Mechanisms of Ventricular and Hemangioblast Specification
R01 HL 11289301/15/13-02/28/18$225,000
Illumination of Mechanisms Controlling Atrial Cell Formation

Wirrig, E

The Role of COX2 in the Progression of Human Calcific Aortic Valve Disease
F32 HL 11039007/01/12-06/30/15$52,190

Yutzey, K

Cell Signaling Mechanisms of Calcific Aortic Valve Disease
R01 HL 11468208/23/12-06/30/16$250,000
Student Undergraduate Research Fellowship
Wnt Signaling in Heart Valve Development and Disease
R01 HL 09431904/15/12-02/28/16$238,000
Twist 1 Regulation of Valve Progenitors
R01 HL 08271607/01/2010-05/31/2015$235,620
Current Year Direct$6,919,459